NewCo News: GSK-Funded Tempero Striking a Balance in Immune Response
By Jennifer Boggs
Monday, April 25, 2011
How does a big pharma firm ensure that early stage research in the hot area of autoimmune diseases doesn't get lost amid expanding late-stage pipelines?
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.